VHL (clone AT82B10), anti-human

Description
Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition todevelop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas andhemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in theVHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-typeallele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet (beta-domain) anda smaller alpha-helical domain (alpha-domain), held together by two linkers and a polar interface. VHL proteinis also involved in the degradation of hypoxia-inducible factor (HIF).Alternative Names
Von Hippel-Lindau tumor suppressor isoform 1, Von Hippel-Lindau tumor suppressor isoform 1,HRCA1, RCA1, VHL1, Von Hippel-Lindau tumor suppressor isoform 1 pVHL, G7 protein, Elongin bindingprotein, HRCA 1, RCA 1, VHL, VHL 1, VHLH, Von Hippel Lindau disease tumor suppressor, vonHippel Lindau syndrome, von Hippel Lindau tumor suppressor, AVH0616Concentration
1mg/ml (determined by BCA assay)Concentration
Liquid in. Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerolStorage: Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.